7 completed, 1 active not recruiting, 1 recruiting, 1 terminated. 10 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 10 | Completed 7, Active not recruiting 1, Recruiting 1, Terminated 1 |
Follow ixekizumab: new trials by email Literature Review of ixekizumab trials Research Report on ixekizumab
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Compare the Pharmacokinetics, Safety, Tolerability, and Immunogenicity of SB35 (Proposed Ixekizumab Biosimilar) to Taltz in Healthy Participants Ixekizumab - Healthy | Phase 1 | Recruiting | Samsung Bioepis Co., Ltd. | 174 | 2026-09-04 | 2026-10-14 |
| Study to Compare Pharmacokinetics and Safety of CT-P52 and US-licensed Taltz in Healthy Subjects Ixekizumab - Healthy Participants | Phase 1 | Active not recruiting | Celltrion | 218 | 2025-09-17 | 2025-12-31 |
| A Study of Two Formulations of Ixekizumab in Healthy Participants Ixekizumab - Healthy | Phase 1 | Completed | Eli Lilly and Company | 245 | 2020-02-05 | 2022-04-08 |
| A Study of Ixekizumab in Healthy Participants Ixekizumab - Healthy | Phase 1 | Completed | Eli Lilly and Company | 99 | 2019-01-29 | 2020-06-24 |
| Study of Ixekizumab in Healthy Participants Ixekizumab - Healthy | Phase 1 | Terminated | Eli Lilly and Company | 70 | 2019-01-29 | 2022-11-30 |
| A Study of Ixekizumab in Chinese Participants With Psoriasis Vulgaris Ixekizumab - Psoriasis | Phase 1 | Completed | Eli Lilly and Company | 32 | 2017-04-13 | 2020-07-22 |
| A Study of Ixekizumab in Participants With Plaque Psoriasis Drug Cocktail, Ixekizumab - Psoriasis | Phase 1 | Completed | Eli Lilly and Company | 28 | 2016-12-22 | 2019-03-12 |
| A Study of the Immune Response to Vaccines and Ixekizumab (LY2439821) in Healthy Participants Ixekizumab, Boostrix®, Pneumovax®23 - Healthy | Phase 1 | Completed | Eli Lilly and Company | 84 | 2015-09-01 | 2017-01-06 |
| A Study of LY2439821 in Rheumatoid Arthritis LY2439821 - Rheumatoid Arthritis | Phase 1 | Completed | Eli Lilly and Company | 28 | 2010-12-01 | 2016-05-26 |
| A Study in Rheumatoid Arthritis LY2439821, Placebo - Rheumatoid Arthritis | Phase 1 | Completed | Eli Lilly and Company | 32 | 2010-05-01 | 2016-05-26 |
Arthritis, Rheumatoid (2) · Psoriasis (2)
Eli Lilly and Company (8) · Celltrion (1) · Samsung Bioepis Co., Ltd. (1)
United States (5) · Japan (2) · South Korea (2) · China (1)